Cardiovascular Diseases, Diabetes Mellitus, Type 2, Overweight, Obesity research hub

J3R-MC-YDAS: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once-Weekly Eloralintide in Adult Participants With Obesity or Overweight, Type 2 Diabetes, and Increased CV Risk

This study is testing a new medicine called eloralintide for adults who have type 2 diabetes, are overweight or obese, and have a higher risk of heart problems. Researchers want to see if taking this once-weekly injection helps people lose weight and safely lower their blood sugar levels.